- Soumettre
- Personnaliser
- Aide
- de
- en
- fr
- it
- visiteur :: identification
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Pivot, X. ; Gligorov, J. ; Müller, V. ; Curigliano, G. ; Knoop, A. ; Verma, S. ; Jenkins, V. ; Scotto, N. ; Osborne, S. ; Fallowfield, L. ; Fallowfield, Lesley ; Jenkins, Valerie ; Kilkerr, Justine ; Langridge, Carolyn ; Monson, Kathryn ; Jakobsen, Erik Hugger ; Nielsen, Mette Holck ; Linnet, Soeren ; Knoop, Ann ; Pivot, Xavier ; Bonnefoi, Herve ; Mousseau, Mireille ; Zelek, Laurent ; Bourgeois, Hugues ; Lefeuvre, Claudia Plesse ; Bachelot, Thomas ; Petit, Thierry ; Brain, Etienne ; Levy, Christelle ; Gligorov, Joseph ; Augustin, Doris ; Graf, Heiko ; Heinrich, Georg ; Kroening, Hendrik ; Kuemmel, Sherko ; Müller, Volkmar ; Overkamp, Friedrich ; Park-Simon, Tjoung-Won ; Schmidt, Marcus ; Perlova-Griff, Lidia ; Wolf, Christopher ; Colleoni, Marco ; Ballestrero, Alberto ; Bernardo, Antonio ; Ribecco, Angela Stefania ; Gianni, Luca ; Curigliano, Giuseppe ; Brewczynska, Elżbieta ; Jassem, Jacek ; Shirinkin, Vadim ; Manikhas, Alexey ; Dvornichenko, Victoria ; Lichinitser, Mikhail ; Semiglazov, Vladimir ; Mukhametshina, Guzel ; Bulavina, Irina ; Arranz, Enrique Espinosa ; Ocon, Francisco Carabantes ; Vivanco, Guillermo López ; Bofill, Javier Salvador ; Quintela, Ignacio Porras ; Muñoz, Alfonso Sanchez ; Pérez, Yolanda Fernández ; Espinosa, Javier Cassinello ; Alvarez, José Valero ; del Prado, Rodrigo Lastra ; Merino, Luis De La Cruz ; García, José Manuel Pérez ; Frances, Santos Enrech ; Edlund, Per ; Norberg, Bengt ; Wennstig, Anna-Karin ; Lind, Pehr ; Hauser, Nik ; Tausch, Christoph ; Camci, Celalettin ; Arpaci, Fikret ; Abali, Huseyin ; Uslu, Ruchan ; Tahir, Saad ; Wheatley, Duncan ; Chan, Stephen ; Barrett-Lee, Peter ; McAdam, Karen ; Simcock, Richard ; Burcombe, Russell ; El-Maraghi, Robert ; Califaretti, Nadia ; Spadafora, Silvana ; Sehdev, Sandeep ; Sami, Amer ; Verma, Sunil
In: Annals of Oncology, 2014, vol. 25, no. 10, p. 1979-1987
Ajouter à la liste personnelleVoir aussi
Liens
Exporter vers
- Titre
-
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
- Auteur
-
- Pivot, X.. Department of Medical Oncology, University Hospital Jean Minjoz, Besançon
- Gligorov, J.. Medical Oncology Department, APHP Hôpital Tenon, Paris
- Müller, V.. Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Curigliano, G.. Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Milan, Italy
- Knoop, A.. Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark
- Verma, S.. Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
- Jenkins, V.. Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Falmer, UK
- Scotto, N.. Global Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland
- Osborne, S.. Global Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland
- Fallowfield, L.. Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Falmer, UK
- Fallowfield, Lesley. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Jenkins, Valerie. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Kilkerr, Justine. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Langridge, Carolyn. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Monson, Kathryn. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Jakobsen, Erik Hugger. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Nielsen, Mette Holck. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Linnet, Soeren. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Knoop, Ann. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Pivot, Xavier. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Bonnefoi, Herve. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Mousseau, Mireille. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Zelek, Laurent. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Bourgeois, Hugues. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Lefeuvre, Claudia Plesse. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Bachelot, Thomas. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Petit, Thierry. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Brain, Etienne. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Levy, Christelle. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Gligorov, Joseph. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Augustin, Doris. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Graf, Heiko. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Heinrich, Georg. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Kroening, Hendrik. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Kuemmel, Sherko. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Müller, Volkmar. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Overkamp, Friedrich. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Park-Simon, Tjoung-Won. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Schmidt, Marcus. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Perlova-Griff, Lidia. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Wolf, Christopher. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Colleoni, Marco. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Ballestrero, Alberto. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Bernardo, Antonio. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Ribecco, Angela Stefania. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Gianni, Luca. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Curigliano, Giuseppe. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Brewczynska, Elżbieta. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Jassem, Jacek. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Shirinkin, Vadim. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Manikhas, Alexey. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Dvornichenko, Victoria. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Lichinitser, Mikhail. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Semiglazov, Vladimir. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Mukhametshina, Guzel. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Bulavina, Irina. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Arranz, Enrique Espinosa. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Ocon, Francisco Carabantes. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Vivanco, Guillermo López. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Bofill, Javier Salvador. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Quintela, Ignacio Porras. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Muñoz, Alfonso Sanchez. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Pérez, Yolanda Fernández. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Espinosa, Javier Cassinello. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Alvarez, José Valero. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- del Prado, Rodrigo Lastra. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Merino, Luis De La Cruz. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- García, José Manuel Pérez. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Frances, Santos Enrech. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Edlund, Per. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Norberg, Bengt. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Wennstig, Anna-Karin. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Lind, Pehr. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Hauser, Nik. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Tausch, Christoph. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Camci, Celalettin. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Arpaci, Fikret. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Abali, Huseyin. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Uslu, Ruchan. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Tahir, Saad. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Wheatley, Duncan. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Chan, Stephen. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Barrett-Lee, Peter. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- McAdam, Karen. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Simcock, Richard. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Burcombe, Russell. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- El-Maraghi, Robert. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Califaretti, Nadia. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Spadafora, Silvana. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Sehdev, Sandeep. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Sami, Amer. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Verma, Sunil. Jean Minjoz, Department of Medical Oncology, University Hospital, Besançon, Medical Oncology Department, Paris, Paris, Department of Gynecology, Hamburg, Early Drug Development for Innovative Therapies Division, Milan, Department of Oncology, Copenhagen, Division of Medical Oncology, Toronto, ON, Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Falmer, Basel, France, Germany, Italy, Denmark, Canada, UK, Switzerland
- Type de document
-
- Postprint
- Langue
-
- Anglais
- Publié dans
-
- Annals of Oncology, 2014, vol. 25, no. 10, p. 1979-1987. Oxford University Press
- Autre version électronique
-
- Publisher's version : https://doi.org/10.1093/annonc/mdu364
- Classification
-
- Santé
- Mots clés
- Identifiant OAI-PMH
-
- oai:doc.rero.ch:302748
- Summary
- PrefHer revealed compelling and consistent patient preference for subcutaneous (s.c.) trastuzumab, regardless of delivery by single-use injection device or hand-held syringe. s.c. trastuzumab was well-tolerated and safety data, including immunogenicity, were consistent with previous reports. No new safety signals were identified compared with the known intravenous trastuzumab profile in early breast cancer